NVNO Quote, Financials, Valuation and Earnings

NeuroOne Medical Technologies Corp. has a net margin of -- compared to enVVeno Medical Corp.'s net margin of -88.5%. enVVeno Medical Corp.'s return on equity of -57.7% beat NeuroOne Medical Technologies Corp.'s return on equity of -166.02%.

enVVeno Medical Corp. has a consensus price target of $12.50, signalling upside risk potential of 3121.65%. On the other hand NeuroOne Medical Technologies Corp. has an analysts' consensus of $2.23 which suggests that it could grow by 231.6%. Given that enVVeno Medical Corp. has higher upside potential than NeuroOne Medical Technologies Corp., analysts believe enVVeno Medical Corp. is more attractive than NeuroOne Medical Technologies Corp..

enVVeno Medical Corp. has a beta of 1.063, which suggesting that the stock is 6.264% more volatile than S&P 500. In comparison NeuroOne Medical Technologies Corp. has a beta of 0.703, suggesting its less volatile than the S&P 500 by 29.673%.

enVVeno Medical Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NeuroOne Medical Technologies Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. enVVeno Medical Corp. pays -- of its earnings as a dividend. NeuroOne Medical Technologies Corp. pays out -- of its earnings as a dividend.

enVVeno Medical Corp. quarterly revenues are --, which are smaller than NeuroOne Medical Technologies Corp. quarterly revenues of $1.7M. enVVeno Medical Corp.'s net income of -$4.5M is lower than NeuroOne Medical Technologies Corp.'s net income of -$1.5M. Notably, enVVeno Medical Corp.'s price-to-earnings ratio is -- while NeuroOne Medical Technologies Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for enVVeno Medical Corp. is 473.07x versus 2.45x for NeuroOne Medical Technologies Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Nutriband, Inc. has a net margin of -- compared to enVVeno Medical Corp.'s net margin of -321.33%. enVVeno Medical Corp.'s return on equity of -57.7% beat Nutriband, Inc.'s return on equity of -117.44%.

enVVeno Medical Corp. has a consensus price target of $12.50, signalling upside risk potential of 3121.65%. On the other hand Nutriband, Inc. has an analysts' consensus of $15.00 which suggests that it could grow by 196.44%. Given that enVVeno Medical Corp. has higher upside potential than Nutriband, Inc., analysts believe enVVeno Medical Corp. is more attractive than Nutriband, Inc..

enVVeno Medical Corp. has a beta of 1.063, which suggesting that the stock is 6.264% more volatile than S&P 500. In comparison Nutriband, Inc. has a beta of 1.907, suggesting its more volatile than the S&P 500 by 90.735%.

enVVeno Medical Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nutriband, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. enVVeno Medical Corp. pays -- of its earnings as a dividend. Nutriband, Inc. pays out -- of its earnings as a dividend.

enVVeno Medical Corp. quarterly revenues are --, which are smaller than Nutriband, Inc. quarterly revenues of $622.5K. enVVeno Medical Corp.'s net income of -$4.5M is lower than Nutriband, Inc.'s net income of -$2M. Notably, enVVeno Medical Corp.'s price-to-earnings ratio is -- while Nutriband, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for enVVeno Medical Corp. is 473.07x versus 21.85x for Nutriband, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Phibro Animal Health Corp. has a net margin of -- compared to enVVeno Medical Corp.'s net margin of 7.29%. enVVeno Medical Corp.'s return on equity of -57.7% beat Phibro Animal Health Corp.'s return on equity of 24.77%.

enVVeno Medical Corp. has a consensus price target of $12.50, signalling upside risk potential of 3121.65%. On the other hand Phibro Animal Health Corp. has an analysts' consensus of $43.00 which suggests that it could grow by 5.47%. Given that enVVeno Medical Corp. has higher upside potential than Phibro Animal Health Corp., analysts believe enVVeno Medical Corp. is more attractive than Phibro Animal Health Corp..

enVVeno Medical Corp. has a beta of 1.063, which suggesting that the stock is 6.264% more volatile than S&P 500. In comparison Phibro Animal Health Corp. has a beta of 0.771, suggesting its less volatile than the S&P 500 by 22.868%.

enVVeno Medical Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Phibro Animal Health Corp. offers a yield of 1.18% to investors and pays a quarterly dividend of $0.12 per share. enVVeno Medical Corp. pays -- of its earnings as a dividend. Phibro Animal Health Corp. pays out 40.46% of its earnings as a dividend. Phibro Animal Health Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

enVVeno Medical Corp. quarterly revenues are --, which are smaller than Phibro Animal Health Corp. quarterly revenues of $363.9M. enVVeno Medical Corp.'s net income of -$4.5M is lower than Phibro Animal Health Corp.'s net income of $26.5M. Notably, enVVeno Medical Corp.'s price-to-earnings ratio is -- while Phibro Animal Health Corp.'s PE ratio is 24.51x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for enVVeno Medical Corp. is 473.07x versus 1.19x for Phibro Animal Health Corp.. Usually stocks with elevated PS ratios are considered overvalued.

SINTX Technologies, Inc. has a net margin of -- compared to enVVeno Medical Corp.'s net margin of -1701.44%. enVVeno Medical Corp.'s return on equity of -57.7% beat SINTX Technologies, Inc.'s return on equity of -208.36%.

enVVeno Medical Corp. has a consensus price target of $12.50, signalling upside risk potential of 3121.65%. On the other hand SINTX Technologies, Inc. has an analysts' consensus of $16.75 which suggests that it could grow by 336.2%. Given that enVVeno Medical Corp. has higher upside potential than SINTX Technologies, Inc., analysts believe enVVeno Medical Corp. is more attractive than SINTX Technologies, Inc..

enVVeno Medical Corp. has a beta of 1.063, which suggesting that the stock is 6.264% more volatile than S&P 500. In comparison SINTX Technologies, Inc. has a beta of 0.633, suggesting its less volatile than the S&P 500 by 36.717%.

enVVeno Medical Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. SINTX Technologies, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. enVVeno Medical Corp. pays -- of its earnings as a dividend. SINTX Technologies, Inc. pays out -- of its earnings as a dividend.

enVVeno Medical Corp. quarterly revenues are --, which are smaller than SINTX Technologies, Inc. quarterly revenues of $208K. enVVeno Medical Corp.'s net income of -$4.5M is lower than SINTX Technologies, Inc.'s net income of -$3.5M. Notably, enVVeno Medical Corp.'s price-to-earnings ratio is -- while SINTX Technologies, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for enVVeno Medical Corp. is 473.07x versus 6.51x for SINTX Technologies, Inc.. Usually stocks with elevated PS ratios are considered overvalued.